
Incorporating Menin Inhibitors into Frontline Therapy for Older Adults with AML: Light at the End of the Tunnel?- ABIM MOC Part 2 - Live
Webinar InformationWebinar Description Discussion on the prognosis, standard management, and advances in the treatment armamentarium of older adults with AML. Menin inhibitors are a new class of targeted agents for AML patients with certain genetic mutations (NPM1-mutation or KMT2A-rearrangements). I will discuss the emerging combination therapy with menin inhibitors for older adults with AML with promising clinical activity for future use. Learning Objectives
|
Webinar DocumentsPoll Everywhere Link Please give poll responses via web at: |
Webinar RegistrationYou must have an account and be logged in to register for and to access the course. Please contact us with any questions at [email protected] or (919) 445–1000. |
![]() | Joshua Zeidner, MD Associate Professor |
DisclosuresActivity Directors ABIM MOC Part 2 Credit ACCME |
Accreditation Statements1.00 ABIM MOC Part 2 Credit 1.00 AMA PRA Category 1 Credit™ |
NoticeIn most cases, regulations prohibit the repeated use of the same educational activity (Live Webinar or Self-Paced, Online Course but not both) as it relates to satisfying CE requirements to maintain licensure. Attendees are also required to view a minimum of 53 minutes of the live webinar video to receive CE credit. Please contact your individual accreditation agencies for more details. Altering or submitting modified certificates constitutes fraud that can result in punitive action by the accrediting agency. |
Available Credit
- 0.00 ABIM Medical Knowledge
- 1.00 AMA PRA Category 1 Credit™

Facebook
X
LinkedIn
Forward